The FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although studies with a longer follow-up period are needed
This study sought to evaluate the efficacy and safety of subcutaneous evolocumab compared with oral ...
The recent development of monoclonal antibodies targeted to proprotein convertase subtilisin/kexin t...
In 2003, select families with familial hypercholesterolemia were first identified to have gain-of-fu...
IMPORTANCE The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first card...
New clinical trials with the proprotein convertase subtilisin- kexin type 9 (PCSK9) inhibitors evolo...
New clinical trials with the proprotein convertase subtilisin- kexin type 9 (PCSK9) inhibitors evolo...
Dirk J Blom,1 Ricardo Dent,2 Rita C Castro,2 Peter P Toth3,4 1Division of Lipidology, Department of ...
Importance: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first car...
peer reviewedBACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subt...
peer reviewedBACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subt...
n the last few years, PCSK9 inhibitors have gained an increasing role in the treatment of dyslipida...
BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin ...
The enzyme PCSK9 has an important role in regulating low-density lipoprotein (LDL) receptors and co...
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). The re...
BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin ...
This study sought to evaluate the efficacy and safety of subcutaneous evolocumab compared with oral ...
The recent development of monoclonal antibodies targeted to proprotein convertase subtilisin/kexin t...
In 2003, select families with familial hypercholesterolemia were first identified to have gain-of-fu...
IMPORTANCE The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first card...
New clinical trials with the proprotein convertase subtilisin- kexin type 9 (PCSK9) inhibitors evolo...
New clinical trials with the proprotein convertase subtilisin- kexin type 9 (PCSK9) inhibitors evolo...
Dirk J Blom,1 Ricardo Dent,2 Rita C Castro,2 Peter P Toth3,4 1Division of Lipidology, Department of ...
Importance: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first car...
peer reviewedBACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subt...
peer reviewedBACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subt...
n the last few years, PCSK9 inhibitors have gained an increasing role in the treatment of dyslipida...
BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin ...
The enzyme PCSK9 has an important role in regulating low-density lipoprotein (LDL) receptors and co...
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). The re...
BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin ...
This study sought to evaluate the efficacy and safety of subcutaneous evolocumab compared with oral ...
The recent development of monoclonal antibodies targeted to proprotein convertase subtilisin/kexin t...
In 2003, select families with familial hypercholesterolemia were first identified to have gain-of-fu...